Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05856526 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase II/III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 43 participants (ACTUAL) |
| Registered Start Date | 2023-06-12 |
| WhyStopped Classification | Unspecified |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | Open Hospital Dossier -> |
| Medical University of South Carolina | Charleston, SC | Open Hospital Dossier -> |
| Westmead Hospital | Westmead, Australia | Open Hospital Dossier -> |
| Beijing Children's Hospital, Capital Medical University | Beijing, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.